Hantz Financial Services Inc. Reduces Holdings in Zoetis Inc. $ZTS

Hantz Financial Services Inc. lowered its position in Zoetis Inc. (NYSE:ZTS) by 10.3% in the 4th quarter, HoldingsChannel reports. The fund owned 152,978 shares of the company’s stock after selling 17,558 shares during the period. Hantz Financial Services Inc.’s holdings in Zoetis were worth $19,248,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. RFG Advisory LLC raised its position in shares of Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after purchasing an additional 80 shares during the period. YANKCOM Partnership grew its stake in Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after buying an additional 81 shares in the last quarter. Beese Fulmer Investment Management Inc. raised its holdings in Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after acquiring an additional 85 shares during the period. Quest 10 Wealth Builders Inc. lifted its position in shares of Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after acquiring an additional 86 shares in the last quarter. Finally, Financial Engines Advisors L.L.C. lifted its position in shares of Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after acquiring an additional 87 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Activity at Zoetis

In other news, Director Frank A. Damelio acquired 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Citigroup reduced their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Finally, UBS Group reduced their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $133.92.

Zoetis Stock Down 0.1%

ZTS stock opened at $81.26 on Monday. The company’s 50 day moving average is $108.11 and its 200 day moving average is $118.47. The stock has a market cap of $34.06 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.6%. Zoetis’s payout ratio is 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.